Published in Cancer on May 01, 2007
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol (2011) 2.95
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst (2012) 2.77
Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst (2008) 2.72
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol (2009) 2.61
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res (2009) 2.59
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer (2008) 2.56
Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat (2010) 2.49
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res (2009) 2.23
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol (2010) 2.20
The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control (2009) 2.14
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09
Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev (2009) 2.00
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther (2010) 1.99
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol (2011) 1.97
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
Breast cancer incidence, stage, treatment and survival in ethnic groups in South East England. Br J Cancer (2009) 1.81
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res (2009) 1.77
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev (2011) 1.71
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.67
Triple-negative breast cancer. Breast Cancer Res (2010) 1.65
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer (2010) 1.62
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat (2008) 1.62
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat (2010) 1.59
Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer (2011) 1.59
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol (2008) 1.56
Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat (2014) 1.56
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Genetic susceptibility to triple-negative breast cancer. Cancer Res (2013) 1.48
Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res (2010) 1.47
Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat (2011) 1.47
Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control (2010) 1.47
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol (2008) 1.46
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
A Model-Based Joint Identification of Differentially Expressed Genes and Phenotype-Associated Genes. PLoS One (2016) 1.39
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. PLoS One (2015) 1.39
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer (2008) 1.38
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res (2011) 1.37
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat (2008) 1.35
Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia (2011) 1.32
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Disparities in screening mammography services by race/ethnicity and health insurance. J Womens Health (Larchmt) (2011) 1.26
Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health (2012) 1.26
Evolutionary foundations for cancer biology. Evol Appl (2013) 1.25
BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer (2012) 1.24
Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol (2009) 1.24
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol (2010) 1.24
An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res (2012) 1.21
Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res (2008) 1.20
Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev (2008) 1.20
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One (2011) 1.19
The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol (2010) 1.18
Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer. Br J Radiol (2011) 1.17
A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium. Cancer Causes Control (2013) 1.17
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer (2013) 1.17
Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond Engl) (2011) 1.16
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer (2010) 1.16
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res (2008) 1.15
Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control (2011) 1.15
Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer (2010) 1.14
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat (2010) 1.14
Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res (2014) 1.13
Molecular therapy of breast cancer: progress and future directions. Nat Rev Endocrinol (2010) 1.13
Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One (2012) 1.11
Admixture mapping identifies a locus on 6q25 associated with breast cancer risk in US Latinas. Hum Mol Genet (2012) 1.11
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol (2014) 1.11
Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prev (2012) 1.10
Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis (2011) 1.10
Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer (2011) 1.10
Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. J Natl Cancer Inst Monogr (2014) 1.09
The impact of age on outcome in early-stage breast cancer. Semin Radiat Oncol (2011) 1.09
Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010. BMC Cancer (2013) 1.09
Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep (2012) 1.08
Prevalence of molecular subtypes and prognosis of invasive breast cancer in north-east of Morocco: retrospective study. BMC Res Notes (2012) 1.08
Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res (2013) 1.08
High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol (2012) 1.07
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus (2012) 1.05
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2012) 1.05
Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci (2012) 1.05
Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol (2010) 1.04
Triple-negative breast cancers: an updated review on treatment options. Curr Oncol (2011) 1.03
Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract (2011) 1.03
Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res (2014) 1.03
Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell (2008) 3.80
Patients' perceptions of quality of care for colorectal cancer by race, ethnicity, and language. J Clin Oncol (2005) 3.30
Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol (2003) 3.18
The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol (2007) 2.19
Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study. J Cancer Surviv (2011) 2.15
Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer (2008) 2.03
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med (2008) 1.79
Ovarian cancer: can we make the clinical diagnosis earlier? Cancer (2005) 1.63
Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol (2009) 1.44
Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer (2010) 1.41
Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol (2003) 1.23
Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol (2007) 1.18
20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab (2013) 1.17
Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer (2010) 1.16
Perineal talc exposure and epithelial ovarian cancer risk in the Central Valley of California. Int J Cancer (2004) 1.13
Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin Genitourin Cancer (2012) 1.11
Using community-based participatory research (CBPR) to develop a community-level HIV prevention intervention for Latinas: a local response to a global challenge. Womens Health Issues (2012) 1.11
Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010. BMC Cancer (2013) 1.09
The relative accuracy of a questionnaire compared with pedigree analysis in genetic risk assessment for infertility. J Urol (2008) 1.08
Condom acquisition and preferences within a sample of sexually active gay and bisexual men in the southern United States. AIDS Patient Care STDS (2007) 1.01
Crystal structure of malaria parasite nucleosome assembly protein: distinct modes of protein localization and histone recognition. J Biol Chem (2009) 1.00
CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog (2011) 0.98
Age-dependent changes in innate immune phenotype and function in rhesus macaques (Macaca mulatta). Pathobiol Aging Age Relat Dis (2012) 0.95
Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res (2011) 0.93
The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study. J Womens Health (Larchmt) (2012) 0.90
Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer (2009) 0.89
Triazine herbicides and epithelial ovarian cancer risk in central California. J Occup Environ Med (2005) 0.89
Epithelial ovarian cancer risk by invasiveness and cell type in the Central Valley of California. Gynecol Oncol (2004) 0.89
Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum. Mol Microbiol (2008) 0.89
Longitudinal assessment of the effect of age and experience on performance in 161-km ultramarathons. Int J Sports Physiol Perform (2014) 0.87
Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev (2005) 0.85
Epidemiologic features of borderline ovarian tumors in California: a population-based study. Cancer Causes Control (2013) 0.85
Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study. Ann Epidemiol (2012) 0.85
Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer (2011) 0.84
Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues. J Am Chem Soc (2013) 0.84
Quality-of-life and surgical treatments for rectal cancer--a longitudinal analysis using the California Cancer Registry. Psychooncology (2010) 0.84
Survival difference between non-Hispanic black and non-Hispanic white women with localized breast cancer: the impact of guideline-concordant therapy. J Natl Med Assoc (2008) 0.84
Utilizing clinical support staff and electronic health records to increase tobacco use documentation and referrals to a state quitline. J Vasc Nurs (2012) 0.82
Factors associated with time to availability for cases reported to population-based cancer registries. Cancer Causes Control (2005) 0.82
Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer. J Thorac Oncol (2010) 0.80
Declining trends of epithelial ovarian cancer in California. Gynecol Oncol (2007) 0.79
Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer. Gynecol Oncol (2007) 0.78
Evolving epidemiologic trends in nonclear cell renal cell cancer: an analysis of the California Cancer Registry. Urology (2013) 0.78
Structure, localization and histone binding properties of nuclear-associated nucleosome assembly protein from Plasmodium falciparum. Malar J (2010) 0.77
Factors affecting treatment delivery and outcomes of patients with early-stage pancreatic adenocarcinoma. Pancreas (2011) 0.77
Acute myeloid leukemia risk by industry and occupation. Leuk Lymphoma (2014) 0.76
Feasibility of linking population-based cancer registries and cancer center biorepositories. Biopreserv Biobank (2012) 0.75
Interscalene block superior to general anesthesia: a discussion of the conclusions regarding these two anesthesia techniques. Anesthesiology (2006) 0.75
Long-bone fracture pain management in the emergency department. J Emerg Nurs (2011) 0.75
Knowledge of Clinical Trial Availability and Reasons for Nonparticipation Among Adolescent and Young Adult Cancer Patients: A Population-based Study. Am J Clin Oncol (2016) 0.75
A method to identify California's sickle-cell disease population and its linkage to the California Cancer Registry. J Registry Manag (2012) 0.75